PART 1. INTRODUCTION
1.1 SCOPE OF THE STUDY
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
PART 2. NORTH AMERICA VACCINES MARKET - KEY TAKEAWAYS
PART 3. NORTH AMERICA VACCINES MARKET - MARKET LANDSCAPE
3.1 OVERVIEW
3.2 MARKET SEGMENTATION
3.2.1 North America Vaccines Market - By Technology
3.2.2 North America Market - By Disease Indication
3.2.3 North America Vaccines Market - By Route of Administration
3.2.4 North America Vaccines Market - By Patient Type
3.2.5 North America Vaccines Market - By Country
3.3 PEST ANALYSIS
PART 4. NORTH AMERICA VACCINES MARKET- KEY MARKET DYNAMICS
4.1 KEY MARKET DRIVERS
4.1.1 Compulsion or Mandate Vaccination
4.1.2 Dropping Vaccination Rates
4.2 KEY MARKET RESTRAINTS
4.2.1 Low Awareness About the Benefits of Vaccines
4.3 KEY MARKET OPPORTUNITIES
4.3.1 Rising Numbers of Diseases
4.4 FUTURE TRENDS
4.4.1 Advances in Vaccine Technology
4.5 IMPACT ANALYSIS
PART 5. VACCINES MARKET - NORTH AMERICA ANALYSIS
5.1 NORTH AMERICA VACCINES MARKET REVENUE FORECASTS AND ANALYSIS
5.2 MARKET POSITIONING
5.3 PERFORMANCE OF KEY PLAYERS
PART 6. NORTH AMERICA VACCINES MARKET ANALYSIS - BY TECHNOLOGY
6.1 OVERVIEW
6.2 NORTH AMERICA VACCINES MARKET, BY TYPE, 2018 & 2027 (%)
6.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
6.4 NORH AMERICA RECOMBINANT VACCINES MARKET
6.4.1 Overview
6.4.2 North America Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.5 NORTH AMERICA CONJUGATE VACCINES MARKET
6.5.1 Overview
6.5.2 North America Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.6 NORTH AMERICA LIVE ATTENUATED VACCINES MARKET
6.6.1 Overview
6.6.2 North America Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.7 NORTH AMERICA INACTIVATED VACCINES MARKET
6.7.1 Overview
6.7.2 North America Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.8 NORTH AMERICA TOXOID VACCINES MARKET
6.8.1 Overview
6.8.2 North America Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
PART 7. NORTH AMERICA VACCINES MARKET ANALYSIS - BY DISEASE INDICATION
7.1 OVERVIEW
7.2 NORTH AMERICA VACCINES MARKET, BY DISEASE INDICATION, 2018 & 2027 (%)
7.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
7.4 NORTH AMERICA DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET
7.4.1 Overview
7.4.2 North America DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
7.5 NORTH AMERICA INFLUENZA MARKET
7.5.1 Overview
7.5.2 North America Influenza Market Revenue and Forecast to 2027 (US$ Mn)
7.6 NORTH AMERICA HEPATITIS MARKET
7.6.1 Overview
7.6.2 North America Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 NORTH AMERICA OTHER DISEASES MARKET
7.7.1 Overview
7.7.2 North America Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
PART 8. NORTH AMERICA VACCINES MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)
8.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
8.4 NORTH AMERICA ORAL MARKET
8.4.1 Overview
8.4.2 North America Oral Market Revenue and Forecast to 2027 (US$ Mn)
8.5 NORTH AMERICA INJECTABLE MARKET
8.5.1 Overview
8.5.2 North America Injectable Market Revenue and Forecast to 2027 (US$ Mn)
8.6 NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET
8.6.1 Overview
8.6.2 North America Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
PART 9. NORTH AMERICA VACCINES MARKET ANALYSIS - BY PATIENT TYPE
9.1 OVERVIEW
9.2 NORTH AMERICA VACCINES MARKET, BY PATIENT TYPE, 2018 & 2027 (%)
9.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
9.4 NORTH AMERICA PEDIATRIC MARKET
9.4.1 Overview
9.4.2 North America Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
9.5 NORTH AMERICA ADULTS MARKET
9.5.1 Overview
9.5.2 North America Adults Market Revenue and Forecast to 2027 (US$ Mn)
PART 10. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027
10.1 OVERVIEW
10.1.1 North America Vaccines Market Revenue And Forecasts to 2027 (US$ Mn)
10.1.2 North America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.3 North America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.4 North America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.5 North America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.6 North America Vaccines Market Revenue And Forecasts to 2027, By Country (%)
10.1.7 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.8.1 US Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.8.2 US Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.8.3 US Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.8.4 US Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.9 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.10 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.10.1 Canada Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.10.2 Canada Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.10.3 Canada Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.10.4 Canada Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.11 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.12 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.12.1 Mexico Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.12.2 Mexico Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.12.3 Mexico Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.12.4 Mexico Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
PART 11. VACCINES MARKET -INDUSTRY LANDSCAPE
11.1 OVERVIEW
11.2 COMPARATIVE COMPANY ANALYSIS
11.3 GROWTH STRATEGIES DONE BY THE COMPANIES IN THE MARKET, (%)
11.4 ORGANIC DEVELOPMENTS
11.4.1 Overview
11.5 INORGANIC DEVELOPMENTS
11.5.1 Overview
PART 12. VACCINES MARKET-KEY COMPANY PROFILES
12.1 PFIZER INC.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Financial Overview
12.1.4 Product Portfolio
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GLAXOSMITHKLINE PLC.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Financial Overview
12.2.4 Product Portfolio
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 MERCK & CO., INC.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Financial Overview
12.3.4 Product Portfolio
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 SANOFI
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Financial Information
12.4.4 Product Portfolio
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 JOHNSON & JOHNSON SERVICES, INC.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Financial Overview
12.5.4 Product Portfolio
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 PANACEA BIOTEC LIMITED
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Financial Information
12.6.4 Product Portfolio
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 ASTELLAS PHARMA INC.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Financial Overview
12.7.4 Product Portfolio
12.7.5 Swot Analysis
12.7.6 Key Developments
12.8 NOVAVAX, INC.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Financial Information
12.8.4 Product Pipeline
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 VBI VACCINES INC.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Financial Information
12.9.4 Product Portfolio
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BAVARIAN NORDIC
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Financial Information
12.10.4 Product Pipeline
12.10.5 SWOT Analysis
12.10.6 Key Developments
PART 13. APPENDIX
13.1 ABOUT THE PUBLISHER
13.2 GLOSSARY OF TERMS
13.3 METHODOLOGY
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research